Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network.
Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H, Saxena R, Kleiner D, Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN). Vuppalanchi R, et al. Among authors: chalasani n. Aliment Pharmacol Ther. 2010 Nov;32(9):1174-83. doi: 10.1111/j.1365-2036.2010.04449.x. Epub 2010 Sep 3. Aliment Pharmacol Ther. 2010. PMID: 20815829 Free PMC article.
Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.
Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Villa-Jimenez O, Lazo-Del Vallin S, Diago M, Adams LA, Romero-Gomez M, Chalasani N. Vilar-Gomez E, et al. Among authors: chalasani n. Aliment Pharmacol Ther. 2017 Jan;45(2):332-344. doi: 10.1111/apt.13860. Epub 2016 Nov 16. Aliment Pharmacol Ther. 2017. PMID: 27862096 Free article.
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Sanyal AJ, et al. Among authors: chalasani n. N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28. N Engl J Med. 2010. PMID: 20427778 Free PMC article. Clinical Trial.
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.
Harrison SA, Marri SR, Chalasani N, Kohli R, Aronstein W, Thompson GA, Irish W, Miles MV, Xanthakos SA, Lawitz E, Noureddin M, Schiano TD, Siddiqui M, Sanyal A, Neuschwander-Tetri BA, Traber PG. Harrison SA, et al. Among authors: chalasani n. Aliment Pharmacol Ther. 2016 Dec;44(11-12):1183-1198. doi: 10.1111/apt.13816. Epub 2016 Oct 24. Aliment Pharmacol Ther. 2016. PMID: 27778367 Free article. Clinical Trial.
Serum proteomic profiling in patients with drug-induced liver injury.
Bell LN, Vuppalanchi R, Watkins PB, Bonkovsky HL, Serrano J, Fontana RJ, Wang M, Rochon J, Chalasani N; US Drug-Induced Liver Injury Network (DILIN) Research Group. Bell LN, et al. Among authors: chalasani n. Aliment Pharmacol Ther. 2012 Mar;35(5):600-12. doi: 10.1111/j.1365-2036.2011.04982.x. Aliment Pharmacol Ther. 2012. PMID: 22403816 Free PMC article.
561 results